CompletedPhase 2NCT00311584
Irinotecan and Temozolomide in Treating Young Patients With Recurrent Neuroblastoma
Studying Neuroblastoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Children's Oncology Group
- Principal Investigator
- Rochelle Bagatell, MDUniversity of Arizona
- Intervention
- irinotecan hydrochloride(drug)
- Enrollment
- 59 target
- Eligibility
- 21 years · All sexes
- Timeline
- 2006 – 2013
Study locations (30)
- Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham, Birmingham, Alabama, United States
- Arizona Cancer Center at University of Arizona Health Sciences Center, Tucson, Arizona, United States
- Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
- Southern California Permanente Medical Group, Downey, California, United States
- Loma Linda University Cancer Institute at Loma Linda University Medical Center, Loma Linda, California, United States
- Jonathan Jaques Children's Cancer Center at Miller Children's Hospital, Long Beach, California, United States
- Childrens Hospital Los Angeles, Los Angeles, California, United States
- Children's Hospital Central California, Madera, California, United States
- Children's Hospital and Research Center Oakland, Oakland, California, United States
- Children's Hospital of Orange County, Orange, California, United States
- Sutter Cancer Center, Sacramento, California, United States
- Kaiser Permanente Medical Center - Oakland, Sacramento, California, United States
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
- Stanford Cancer Center, Stanford, California, United States
- Children's Hospital Center for Cancer and Blood Disorders, Aurora, Colorado, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00311584 on ClinicalTrials.govOther trials for Neuroblastoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2, PHASE3NCT07549321A Safety and Efficacy Study of hu14 in High-Risk Neuroblastoma PatientsRenaissance Pharma Ltd.
- RECRUITINGPHASE1, PHASE2NCT06625190Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid TumorsUniversity of Florida
- RECRUITINGPHASE1NCT07172958Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)Children's National Research Institute
- RECRUITINGPHASE2NCT07085338A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory NeuroblastomaSt. Jude Children's Research Hospital
- RECRUITINGPHASE1, PHASE2NCT07399821An Imaging Study of Anti-GD2-800CW in Patients With NeuroblastomaPrincess Maxima Center for Pediatric Oncology
- RECRUITINGPHASE1NCT06995872Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory NeuroblastomaNational Cancer Institute (NCI)
- RECRUITINGPHASE1, PHASE2NCT06814496Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing TumorsUniversity of Arizona
- RECRUITINGPHASE1NCT07087002GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young AdultsStanford University